Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
274
Completed, industry sponsors, Neurology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed274
274 trials
Showing 1 to 25, recently updated first.
HealthTech Wound CareIndustry
NCT07172893 · 150 participants · Start Dec 10, 2025 · Primary completion Oct 1, 2026
Drug: DermaBind TL · For: Diabetic Foot Ulcer (DFU); Venous Leg Ulcer (VLU)
Sites: DeLand, Florida; Palm Beach Gardens, Florida; Sweetwater, Florida · 10 sites in all
Lantheus Biosciences Ltd.Industry
NCT02681172 · 218 participants · Start Oct 2015 · Primary completion Sep 2016
Drug: Neuraceq (florbetaben 18F) · For: Alzheimer's Disease (AD)
Sites: Marseille, France
H. Lundbeck A/SIndustry
NCT06701526 · 164 participants · Start Dec 18, 2024 · Primary completion Sep 2, 2026
Drug: Eptinezumab · For: Migraine
Sites: Phoenix, Arizona; Little Rock, Arkansas; San Marcos, California · 21 sites in all
- Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of MigraineCompleted
Zogenix, Inc.Industry
NCT01016834 · 246 participants · Start Nov 30, 2009 · Primary completion Apr 30, 2010
Drug: Sumatriptan · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Newport Beach, California · 21 sites in all
- Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive MedicationsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05518123 · 962 participants · Start Nov 7, 2022 · Primary completion Mar 31, 2025
Drug: Rimegepant; Placebo · For: Migraine
Sites: Los Angeles, California; Sherman Oaks, California; Stamford, Connecticut · 111 sites in all
- Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan UsePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05509400 · 813 participants · Start Oct 18, 2022 · Primary completion Mar 10, 2025
Drug: Rimegepant; Placebo and 1 more · For: Migraine
Sites: Los Angeles, California; Stamford, Connecticut; Lake City, Florida · 93 sites in all
- A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During PregnancyCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04998812 · 70 participants · Start Apr 13, 2022 · Primary completion Apr 8, 2024
Drug: Ocrelizumab · For: Multiple Sclerosis; Clinically Isolated Syndrome
Sites: San Francisco, California; Aurora, Colorado; Chicago, Illinois · 11 sites in all
- Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigrainePivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04252742 · 512 participants · Start Sep 15, 2020 · Primary completion Oct 26, 2023
Drug: Erenumab; Placebo · For: Migraine
Sites: Long Beach, California; Los Angeles, California; Basalt, Colorado · 91 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05084638 · 180 participants · Start Jan 25, 2022 · Primary completion Feb 4, 2025
Drug: Ofatumumab · For: Relapse Remitting Multiple Sclerosis
Sites: Chandler, Arizona; Phoenix, Arizona; Los Angeles, California · 36 sites in all
- Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's DiseasePivotal-lookingCompleted
Carnot LaboratoriesIndustry
NCT07417670 · 105 participants · Start Oct 4, 2024 · Primary completion Aug 12, 2025
Drug: Memantine; Memantine Oral Tablet · For: Alzheimer Disease
Sites: Saltillo, Mexico; Guadalajara, Mexico; Monterrey, Mexico · 4 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04377555 · 179 participants · Start Jul 30, 2020 · Primary completion Dec 15, 2022
Drug: Ocrelizumab · For: Multiple Sclerosis, Relapsing
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 28 sites in all
- A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadachePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT05452239 · 608 participants · Start Jul 1, 2022 · Primary completion Oct 22, 2024
Drug: Eptinezumab; Placebo · For: Migraine; Medication Overuse Headache
Sites: Winter Haven, Florida; Marrero, Louisiana; Springfield, Missouri · 76 sites in all
- A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving OcrelizumabCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04998851 · 26 participants · Start Sep 16, 2021 · Primary completion Mar 29, 2024
Drug: Ocrelizumab · For: Multiple Sclerosis; Clinically Isolated Syndrome
Sites: San Francisco, California; Aurora, Colorado; Chicago, Illinois · 8 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04667949 · 98 participants · Start Feb 20, 2021 · Primary completion Mar 25, 2025
Drug: Fingolimod 0.5mg · For: Relapsing Multiple Sclerosis (RMS)
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 13 sites in all
- Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in ChinaCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05199571 · 99 participants · Start Jul 22, 2022 · Primary completion Feb 13, 2025
Drug: Ofatumumab · For: Relapsing Multiple Sclerosis
Sites: Lanzhou, China; Guangzhou, China; Shijiazhuang, China · 18 sites in all
- Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05217927 · 1,415 participants · Start Mar 4, 2022 · Primary completion Oct 22, 2024
Drug: Rimegepant 75mg daily dosing; Rimegepant 75mg every other day dosing and 1 more · For: Migraine
Sites: Tempe, Arizona; Colton, California; Los Angeles, California · 107 sites in all
PharmasoftIndustry
NCT06437639 · 80 participants · Start Sep 15, 2023 · Primary completion Nov 29, 2023
Drug: Mexidol · For: Primary Open-Angle Glaucoma (POAG)
Sites: Tyumen, Russia
SanofiSanofi (SNY)
NCT04410965 · 82 participants · Start May 20, 2020 · Primary completion Jul 12, 2021
Drug: TERIFLUNOMIDE · For: Multiple Sclerosis
Sites: China, China
- A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadachePivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03971071 · 620 participants · Start Oct 7, 2019 · Primary completion Dec 1, 2022
Drug: Erenumab 70 mg; Erenumab 140 mg and 1 more · For: Migraine Headache
Sites: Cerritos, California; Colton, California; Los Angeles, California · 94 sites in all
PfizerPfizer (PFE)
NCT05207865 · 441 participants · Start Mar 15, 2022 · Primary completion Jul 2, 2024
Drug: Rimegepant · For: Migraine; Episodic Migraine; Phonophobia and 1 more
Sites: Phoenix, Arizona; Hawthorne, California; North Hollywood, California · 19 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03715205 · 150 participants · Start Jan 31, 2019 · Primary completion Aug 21, 2024
Drug: Pembrolizumab · For: Carcinoma, Non-Small-Cell Lung; Melanoma
Sites: Hyderabad, India; Gurgaon, India; Mumbai, India · 8 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04489888 · 101 participants · Start Oct 27, 2020 · Primary completion Feb 20, 2023
Drug: Pembrolizumab; Carboplatin and 1 more · For: Squamous Cell Carcinoma of Head and Neck
Sites: New Haven, Connecticut; Newark, Delaware; Jacksonville, Florida · 35 sites in all
BiogenBiogen (BIIB)
NCT05658484 · 60 participants · Start Jun 9, 2023 · Primary completion Mar 27, 2025
Drug: Dimethyl fumarate · For: Multiple Sclerosis
Sites: Beijing, China; Changsha, China; Chengdu, China · 15 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04869358 · 34 participants · Start May 27, 2021 · Primary completion May 10, 2022
Drug: Ofatumumab · For: Relapsing Multiple Sclerosis
Sites: Berlin, Germany; Bielefeld, Germany; Dresden, Germany · 6 sites in all
- Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral NeuropathyPivotal-lookingCompleted
Yuhan CorporationIndustry
NCT04846673 · 151 participants · Start May 14, 2021 · Primary completion Nov 30, 2022
Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg; Pregabalin 150mg and 1 more · For: Diabetic Peripheral Neuropathy
Sites: Busan, South Korea; Gwangju, South Korea; Gyeonggi-do, South Korea · 14 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.